論文

査読有り 国際誌
2018年9月

Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.

The British journal of radiology
  • Yoshitaka Honma
  • ,
  • Takashi Terauchi
  • ,
  • Ukihide Tateishi
  • ,
  • Daisuke Kano
  • ,
  • Kengo Nagashima
  • ,
  • Hirokazu Shoji
  • ,
  • Satoru Iwasa
  • ,
  • Atsuo Takashima
  • ,
  • Ken Kato
  • ,
  • Tetsuya Hamaguchi
  • ,
  • Narikazu Boku
  • ,
  • Yasuhiro Shimada
  • ,
  • Yasuhide Yamada

91
1089
開始ページ
20180259
終了ページ
20180259
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1259/bjr.20180259

OBJECTIVE: Peritoneal metastasis (PM) is the most frequent form of metastasis in gastric cancer (GC). The sensitivity of detecting PM by pre-operative imaging modalities is low. Utility of positron emission tomography (PET) with 18F-fluodeoxyglucose (FDG) for GC is limited, because diffuse-type tumors are not FDG-avid. 18F-fluothymidine ([F-18]FLT) is a radiotracer that reflects cellular proliferation and the utility of [F-18]FLT-PET in GC has been reported. In this proof-of-concept study, we explored the ability of [F-18]FLT-PET/CT to detect PM of GC previously identified by other imaging modalities. METHODS: The key eligibility criteria were as follows; (i) histologically proven gastric adenocarcinoma; (ii) evident PM detected by CT performed within 4 weeks prior to registration; (iii) no prior treatment of PM within 4 weeks before registration. [F-18]FLT-PET/CT was performed at National Cancer Center Hospital, and [F-18]FLT-PET/CT images were evaluated independently by two radiologists. Safety assessments were carried out before and after [F-18]FLT-PET/CT. The primary end point was the detection sensitivity of PM. RESULTS: A total of 19 eligible patients were analyzed, of which 15 (78.9%) had diffuse-type histology. Detection sensitivity of PM, primary lesion, and lymph node metastasis were 73.7% [maximum standardized uptake value (SUVmax): 1.697-13.21], 100% (SUVmax: 2.71-22.01), and 72.7% (SUVmax: 2.079-12.61), respectively. No patients experienced adverse events during or after [F-18]FLT-PET/CT. CONCLUSION: This proof-of-concept study shows that [F-18]FLT-PET/CT is a sensitive method for detecting PM in GC, and paves the way for future studies investigating the clinical utility of this approach for the detection of clinically non-evident PM in GC. Advances in knowledge: This proof-of-concept study found that [F-18]FLT-PET/CT is a sensitive method for detecting peritoneal metastases in GC.

リンク情報
DOI
https://doi.org/10.1259/bjr.20180259
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29916721
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223173

エクスポート
BibTeX RIS